Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Key Points

• Rep. Gilbert Ray Cisneros, Jr. disclosed a purchase of Tandem Diabetes Care (NASDAQ:TNDM) stock valued between $1,001 and $15,000 on March 3 in his "150 MAIN STREET TRUST > BANK OF AMERICA" account.
• TNDM traded up ~2.2% to $19.77 with a market cap of $1.35B; the company reported a revenue beat but negative EPS and margins, and analysts hold a consensus “Hold” rating with an average target of $29.06.
• On March 27, Cisneros executed multiple other trades across financial and tech names—most notably a larger purchase of Fabrinet (NYSE:FN) valued between $15,001 and $50,000—alongside several $1,001–$15,000 buys and sells.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Tandem Diabetes Care stock on March 3rd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of MACOM Technology Solutions NASDAQ: MTSI on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of StandardAero NYSE: SARO on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of FirstService NASDAQ: FSV on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Advanced Energy Industries NASDAQ: AEIS on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Flex NASDAQ: FLEX on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of LPL Financial NASDAQ: LPLA on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 3/27/2026.
• Purchased $15,001 - $50,000 in shares of Fabrinet NYSE: FN on 3/27/2026.

Tandem Diabetes Care Trading Up 2.2%

TNDM stock traded up $0.42 during trading on Thursday, hitting $19.77. The company had a trading volume of 327,537 shares, compared to its average volume of 1,962,978. Tandem Diabetes Care, Inc. has a 52-week low of $9.98 and a 52-week high of $29.65. The company has a 50 day simple moving average of $21.53 and a 200-day simple moving average of $19.47. The firm has a market capitalization of $1.35 billion, a P/E ratio of -6.44 and a beta of 1.74. The company has a quick ratio of 2.02, a current ratio of 2.55 and a debt-to-equity ratio of 2.00.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Thursday, February 19th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.04. The company had revenue of $290.38 million during the quarter, compared to analysts' expectations of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The firm's quarterly revenue was up 15.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.01 EPS. As a group, research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TNDM. Canaccord Genuity Group set a $35.00 price target on Tandem Diabetes Care and gave the company a "buy" rating in a report on Wednesday, December 17th. Sanford C. Bernstein reaffirmed a "market perform" rating and set a $25.00 target price (up from $18.00) on shares of Tandem Diabetes Care in a research report on Friday, January 9th. Royal Bank Of Canada reissued an "outperform" rating and set a $30.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday, December 17th. Mizuho set a $22.00 price target on Tandem Diabetes Care and gave the company a "neutral" rating in a research note on Friday, February 20th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Tandem Diabetes Care in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $29.06.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Freestone Grove Partners LP purchased a new stake in shares of Tandem Diabetes Care during the third quarter worth about $22,706,000. Ophir Asset Management Pty Ltd acquired a new stake in Tandem Diabetes Care in the 2nd quarter worth approximately $27,307,000. Assenagon Asset Management S.A. purchased a new stake in Tandem Diabetes Care during the 4th quarter worth approximately $26,988,000. First Light Asset Management LLC purchased a new stake in Tandem Diabetes Care during the 4th quarter worth approximately $23,947,000. Finally, BNP Paribas Financial Markets increased its stake in Tandem Diabetes Care by 468.5% during the 4th quarter. BNP Paribas Financial Markets now owns 1,248,481 shares of the medical device company's stock valued at $27,442,000 after purchasing an additional 1,028,866 shares in the last quarter.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.